|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Dicker D, Pain A, Hamavid H,
Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et
al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cabrera R and Nelson DR: Review article:
The management of hepatocellular carcinoma. Aliment Pharmacol Ther.
31:461–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marrero JA and Welling T: Modern diagnosis
and management of hepatocellular carcinoma. Clin Liver Dis.
13:233–247. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Forner A, Hessheimer AJ, Isabel Real M and
Bruix J: Treatment of hepatocellular carcinoma. Crit Rev Oncol
Hematol. 60:89–98. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ishizawa T, Hasegawa K, Aoki T, Takahashi
M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N and Makuuchi M:
Neither multiple tumors nor portal hypertension are surgical
contraindications for hepatocellular carcinoma. Gastroenterology.
134:1908–1916. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu MC and Yuan JM: Environmental factors
and risk for hepatocellular carcinoma. Gastroenterology 127 (5
Suppl 1). S72–S78. 2004.
|
|
9
|
Borchert GM, Lanier W and Davidson BL: RNA
polymerase III transcribes human microRNAs. Nat Struct Mol Biol.
13:1097–1101. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klingenberg M, Matsuda A, Diederichs S and
Patel T: Non-coding RNA in hepatocellular carcinoma: Mechanisms,
biomarkers and therapeutic targets. J Hepatol. 67:603–618. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weidle UH, Birzele F, Kollmorgen G and
Nopora A: Potential microRNA-related targets for therapeutic
intervention with ovarian cancer metastasis. Cancer Genomics
Proteomics. 15:1–15. 2018.PubMed/NCBI
|
|
13
|
Celano M, Rosignolo F, Maggisano V, Pecce
V, Iannone M, Russo D and Bulotta S: MicroRNAs as Biomarkers in
Thyroid Carcinoma. Int J Genomics. 2017:64965702017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Irmak-Yazicioglu MB: Mechanisms of
microRNA deregulation and microRNA targets in gastric cancer. Oncol
Res Treat. 39:136–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Yang L, Wang S, Liu Z and Xiu M:
MiR-29a suppresses cell proliferation by targeting SIRT1 in
hepatocellular carcinoma. Cancer Biomark. 22:151–159. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li H, Wang H and Ren Z: MicroRNA-214-5p
inhibits the invasion and migration of hepatocellular carcinoma
cells by targeting Wiskott-Aldrich syndrome like. Cell Physiol
Biochem. 46:757–764. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu M, Huang C, Huang X, Liang R, Feng Y
and Luo X: MicroRNA-144-3p suppresses tumor growth and angiogenesis
by targeting SGK3 in hepatocellular carcinoma. Oncol Rep.
38:2173–2181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hayes CN and Chayama K: MicroRNAs as
biomarkers for liver disease and hepatocellular carcinoma. Int J
Mol Sci. 17:2802016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Anwar SL and Lehmann U: MicroRNAs:
Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas. J
Clin Med. 4:1631–1650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Z, Wang Y, Dou C, Sun L, Li Q, Wang L,
Xu Q, Yang W, Liu Q and Tu K: MicroRNA-1468 promotes tumor
progression by activating PPAR-gamma-mediated AKT signaling in
human hepatocellular carcinoma. J Exp Clin Cancer Res. 37:492018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liang S, Zhang N, Deng Y, Chen L, Zhang Y,
Zheng Z, Luo W, Lv Z, Li S and Xu T: miR-663b promotes tumor cell
proliferation, migration and invasion in nasopharyngeal carcinoma
through targeting TUSC2. Exp Ther Med. 14:1095–1103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Du M, Shi D, Yuan L, Li P, Chu H, Qin C,
Yin C, Zhang Z and Wang M: Circulating miR-497 and miR-663b in
plasma are potential novel biomarkers for bladder cancer. Sci Rep.
5:104372015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shu Y, Ye W, Gu YL and Sun P: Blockade of
miR-663b inhibits cell proliferation and induces apoptosis in
osteosarcoma via regulating TP73 expression. Bratisl Lek Listy.
119:41–46. 2018.PubMed/NCBI
|
|
24
|
Wang YL, Shen Y, Xu JP, Han K, Zhou Y,
Yang S, Yin JY, Min DL and Hu HY: Pterostilbene suppresses human
endometrial cancer cells in vitro by down-regulating miR-663b. Acta
Pharmacol Sin. 38:1394–1400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Faria SC, Szklaruk J, Kaseb AO, Hassabo HM
and Elsayes KM: TNM/Okuda/Barcelona/UNOS/clip international
multidisciplinary classification of hepatocellular carcinoma:
Concepts, perspectives, and radiologic implications. Abdom Imaging.
39:1070–1087. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu X, He B, Zhou L, Xie H and Zheng S:
Expression pattern and clinical significance of Gab2 protein in
hepatocellular carcinoma. Clin Lab. 62:1087–1092. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Y, Liu Q, Wu M, Li M, Ding H, Shan X,
Liu J, Tao T, Ni R and Chen X: GAB2 promotes cell proliferation by
activating the ERK signaling pathway in hepatocellular carcinoma.
Tumour Biol. 37:11763–11773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng J, Zhong Y, Chen S, Sun Y, Huang L,
Kang Y, Chen B, Chen G, Wang F, Tian Y, et al: Gab2 mediates
hepatocellular carcinogenesis by integrating multiple signaling
pathways. FASEB J. 31:5530–5542. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang T, Liu W, Meng W, Zhao H, Yang Q, Gu
SJ, Xiao CC, Jia CC and Fu BS: Downregulation of miR-542-3p
promotes cancer metastasis through activating TGF-beta/Smad
signaling in hepatocellular carcinoma. Onco Targets Ther.
11:1929–1939. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cui H, Song R, Wu J, Wang W, Chen X and
Yin J: MicroRNA-337 regulates the PI3K/AKT and Wnt/β-catenin
signaling pathways to inhibit hepatocellular carcinoma progression
by targeting high-mobility group AT-hook 2. Am J Cancer Res.
8:405–421. 2018.PubMed/NCBI
|
|
32
|
Morishita A and Tsutomu M: MicroRNAs as
possible biomarkers for hepatocellular carcinoma. Hepatol Res.
48:499–501. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai H, An Y, Chen X, Sun D, Chen T, Peng
Y, Zhu F, Jiang Y and He X: Epigenetic inhibition of miR-663b by
long non-coding RNA HOTAIR promotes pancreatic cancer cell
proliferation via up-regulation of insulin-like growth factor 2.
Oncotarget. 7:86857–86870. 2016. View Article : Google Scholar : PubMed/NCBI
|
